John Trizzino - Sep 13, 2021 Form 4 Insider Report for NOVAVAX INC (NVAX)

Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Sep 13, 2021
Transactions value $
-$3,252,632
Form type
4
Date filed
9/15/2021, 05:03 PM
Previous filing
Aug 20, 2021
Next filing
Sep 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise $143K +7.5K +1044.43% $19.08 8.22K Sep 13, 2021 Direct F1
transaction NVAX Common Stock Sale -$99.2K -429 -5.22% $231.29 7.79K Sep 13, 2021 Direct F1, F2
transaction NVAX Common Stock Sale -$306K -1.32K -16.91% $232.24 6.47K Sep 13, 2021 Direct F1, F3
transaction NVAX Common Stock Sale -$298K -1.28K -19.77% $233.25 5.19K Sep 13, 2021 Direct F1, F4
transaction NVAX Common Stock Sale -$256K -1.09K -21.01% $234.26 4.1K Sep 13, 2021 Direct F1, F5
transaction NVAX Common Stock Sale -$305K -1.29K -31.53% $235.50 2.81K Sep 13, 2021 Direct F1, F6
transaction NVAX Common Stock Sale -$208K -880 -31.34% $236.38 1.93K Sep 13, 2021 Direct F1, F7
transaction NVAX Common Stock Sale -$117K -493 -25.57% $237.84 1.44K Sep 13, 2021 Direct F1, F8
transaction NVAX Common Stock Sale -$15.7K -66 -4.6% $238.13 1.37K Sep 13, 2021 Direct F1, F9
transaction NVAX Common Stock Sale -$18K -74 -5.41% $242.62 1.3K Sep 13, 2021 Direct F1, F10
transaction NVAX Common Stock Sale -$81.6K -333 -25.71% $245.16 962 Sep 13, 2021 Direct F1, F11
transaction NVAX Common Stock Sale -$60.3K -244 -25.36% $247.33 718 Sep 13, 2021 Direct F1, F12
transaction NVAX Common Stock Options Exercise $143K +7.5K +1044.43% $19.08 8.22K Sep 14, 2021 Direct F1
transaction NVAX Common Stock Sale -$209K -898 -10.93% $233.17 7.32K Sep 14, 2021 Direct F1, F13
transaction NVAX Common Stock Sale -$212K -905 -12.37% $233.90 6.41K Sep 14, 2021 Direct F1, F14
transaction NVAX Common Stock Sale -$160K -682 -10.63% $235.16 5.73K Sep 14, 2021 Direct F1, F15
transaction NVAX Common Stock Sale -$336K -1.42K -24.81% $236.16 4.31K Sep 14, 2021 Direct F1, F16
transaction NVAX Common Stock Sale -$189K -799 -18.54% $237.14 3.51K Sep 14, 2021 Direct F1, F17
transaction NVAX Common Stock Sale -$339K -1.42K -40.53% $238.10 2.09K Sep 14, 2021 Direct F1, F18
transaction NVAX Common Stock Sale -$135K -564 -27.01% $238.95 1.52K Sep 14, 2021 Direct F1, F19
transaction NVAX Common Stock Sale -$142K -590 -38.71% $240.37 934 Sep 14, 2021 Direct F1, F20
transaction NVAX Common Stock Sale -$52.2K -216 -23.13% $241.70 718 Sep 14, 2021 Direct F1, F21

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 -7.5K -5.36% $0.00 133K Sep 13, 2021 Common Stock 7.5K $19.08 Direct F1, F22
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 -7.5K -5.66% $0.00 125K Sep 14, 2021 Common Stock 7.5K $19.08 Direct F1, F22
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.81 to $231.77, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.83 to $232.82, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $232.85 to $233.83, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F5 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233.85 to $234.81, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F6 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.93 to $235.92, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F7 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.93 to $236.79, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F8 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.01 to $237.95, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F9 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $238.04 to $238.85, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F10 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.60 to $242.63, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F11 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.13 to $245.17, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F12 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.01 to $247.74, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F13 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $232.52 to $233.48, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F14 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233.55 to $234.27, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F15 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.62 to $235.61, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F16 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.64 to $236.56, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F17 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.68 to $237.65, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F18 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.71 to $238.52, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F19 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $238.71 to $239.43, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F20 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.07 to $240.98, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F21 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.66 to $241.75, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F22 On April 17, 2020, the reporting person was granted an option to purchase 140,000 shares of common stock of Novavax, Inc. (the "Company") pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date.